Exact Sciences Buyout: What Happens to Your Stock?
The recent announcement that Abbott will acquire Exact Sciences has raised many questions—and understandable concerns—for employees and investors holding Exact Sciences stock. Whether you’re an employee with equity compensation or a shareholder with a significant investment, you’re now facing important decisions about what to do next. Understanding the specifics of how this buyout affects your vested and unvested shares, stock options, and overall financial plan is crucial to making informed choices during this time of transition.
This guide will walk you through the key considerations specific to the Exact Sciences acquisition by Abbott. We’ll cover what happens to your vested and unvested shares, how the Employee Stock Purchase Plan (ESPP) is expected to be handled, and outline the main tax implications you may face. With this information, you can develop a plan to navigate the transition and make the most of this significant event.
Should I Sell My Vested Stock Before the Deal Closes?
When Abbott announced its plan to acquire Exact Sciences, EXAS shares quickly surged toward the acquisition price of $105 per share. On the day the news broke, the stock jumped above $100, reflecting the market’s expectation that the deal would proceed. However, you may notice that EXAS doesn’t always trade precisely at $105. This small difference represents the risk that the acquisition could still fall through before shareholder and regulatory approvals are secured. If the deal were to collapse, the stock price could drop significantly. As the closing date approaches and approvals become more certain, the stock price typically stabilizes closer to the agreed-upon price.
For Exact Sciences stockholders, deciding whether to sell your vested EXAS shares now or wait for the Abbott deal to close requires careful consideration of your personal financial situation, your appetite for risk, and your tax planning strategy. Some shareholders may prefer to lock in their gains while the stock is trading near the acquisition price, avoiding the risk that the deal might not go through. Others may choose to hold out for the full $105 per share if they are comfortable with the small remaining uncertainty and their financial plans allow for it. Your individual circumstances—including your income needs, overall investment portfolio, and upcoming tax liabilities—should all play a role in this decision. Consulting with a financial advisor familiar with the specifics of this buyout can help ensure your choice aligns with your broader financial goals.
Tax planning is especially important for Exact Sciences stockholders in light of the Abbott acquisition. Since the announcement came late in 2025 but the deal is expected to close in 2026, you may be able to manage when you recognize your gains and the corresponding tax impact. For example, selling some shares before the end of 2025 allows you to realize some gains in this tax year, potentially smoothing the impact of a large transaction and spreading your tax liability across two years rather than incurring it all in 2026. Given the size of the potential payout and its effect on your personal tax bracket, timing your sales and understanding your specific tax situation are both critical. Consulting with a financial advisor who understands the details of this acquisition and your individual financial picture can help you determine the most tax-efficient strategy.
What About My Unvested RSUs and PSUs?
For Exact Sciences employees, much of your equity compensation comes in the form of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). The Abbott acquisition constitutes a “change in control,” which is a scenario specifically covered in Exact Sciences’ long-term incentive plans.
According to current communications, all unvested RSUs will accelerate and become fully vested immediately upon closing of the deal. These shares will then be paid out in cash based on the $105 per share acquisition price. This accelerated vesting means that even RSUs scheduled to vest in future years will vest and settle in cash as soon as the transaction is finalized. Because this payout is considered ordinary income, like your regular wages, it can result in a substantial increase in taxable income for the year in which the deal closes.
The treatment of PSUs is typically more complicated. For Exact Sciences employees, PSUs may become vested on a prorated basis depending on how close the company is to reaching performance targets at the time of acquisition. However, the plan documents and preliminary guidance suggest that, much like RSUs, outstanding PSUs are also likely to vest (at least partially, if not fully) and be paid out in cash when the deal closes. As with accelerated RSUs, this payout will be subject to ordinary income tax.
While it’s theoretically possible for an acquiring company to convert unvested equity into their own shares, Abbott’s deal for Exact Sciences is structured as an all-cash transaction, so employees should expect to receive a lump-sum cash payout for both RSUs and PSUs that vest at the closing date.
How Are Employee Stock Purchase Plans (ESPPs) Handled?
If you participate in Exact Sciences’ Employee Stock Purchase Plan (ESPP), the shares you’ve purchased will be treated the same as common stock during the Abbott acquisition. When the deal closes, all ESPP shares you hold will be cashed out at the agreed-upon acquisition price of $105 per share. This means you won’t have a choice about the timing of the sale—your ESPP shares will automatically be sold as part of the transaction, and you’ll receive cash for them soon after closing. You should expect Abbott to communicate details about the wind-down or transition of the ESPP before the acquisition is finalized and, if eligible, you may have the opportunity to join Abbott’s ESPP in the future.
The tax implications for ESPP shares in the Exact Sciences-Abbott acquisition will depend on how long you've held those shares, and whether the sale counts as a "qualifying disposition" or a "disqualifying disposition" under IRS rules.
- Qualifying Disposition: For ESPP shares to receive the most favorable tax treatment, you must have held them for more than two years from the offering (grant) date and more than one year from the purchase date. In a qualifying disposition, part of the gain is taxed as ordinary income (usually the discount you received when buying the shares), and the remainder is taxed at the typically lower long-term capital gains rate.
- Disqualifying Disposition: If you haven’t met both holding periods when the acquisition closes, the sale will be considered a disqualifying disposition. In this scenario, more of your gain is taxed as ordinary income, and less is taxed at the capital gains rate.
Because the Abbott acquisition is expected to force the sale of all your Exact Sciences ESPP shares at closing—regardless of your personal timing—many employees may find themselves subject to disqualifying disposition rules, even if they would have preferred to hold their shares longer. This makes it especially important to review your grant and purchase dates and to seek guidance from your tax advisor about the implications in your specific situation.
Planning for the Tax Implications
The Exact Sciences acquisition by Abbott—because it is an all-cash deal—will trigger a significant taxable event for most shareholders and employees. The type and amount of taxes you owe will depend on whether your shares are vested or unvested, how and when you acquired them, and the accounts in which they’re held.
- Vested RSUs: When your RSUs vested, you paid ordinary income tax on their value at that time. This value established your cost basis. When the shares are sold in the acquisition, you will pay capital gains tax on the difference between the sale price and your cost basis. If the deal closes more than a year after vesting, it's a long-term capital gain; if less than a year, it's a short-term capital gain.
- Accelerated RSUs: Unvested RSUs that accelerate at closing are different. You will owe ordinary income tax on the entire value of these shares at the acquisition price, as you have not previously paid tax on them.
- ESPP Shares: As discussed, the tax treatment depends on whether the sale is a qualifying or disqualifying disposition.
- Shares in a 401(k): If you hold company stock within your 401(k), the shares will be sold, but there are no immediate tax implications. The cash proceeds remain within your 401(k) and will need to be reinvested into other funds available in the plan. Taxes will only be due when you withdraw funds from your pre-tax 401(k) in retirement.
Strategies to Potentially Lower Your Tax Bill
The Abbott acquisition gives Exact Sciences stockholders a unique window to focus on tax planning. Because you may receive a large lump sum from shares or equity awards, your total income for the year could spike, potentially pushing you into a higher tax bracket. Taking steps now can help manage your tax exposure and make the most of this one-time event. Here are some strategies to consider as you navigate this transition:
- Tax-Loss Harvesting: Review your other investment accounts for any positions that have unrealized losses. Selling these positions can generate losses that offset the capital gains from your company stock sale.
- Donate Appreciated Stock: If you are charitably inclined, donating highly appreciated shares directly to a qualified charity or a Donor-Advised Fund (DAF) is a powerful strategy. You can typically deduct the full fair market value of the stock and avoid paying capital gains taxes on the growth.
- Defer or Delay other income in 2026
- Maximize Pre-Tax Contributions: Increase contributions to your 401(k), Health Savings Account (HSA), or other tax-deferred accounts to reduce your taxable income for the year.
What Should I Do with the Cash?
Receiving a substantial cash payout from the Exact Sciences acquisition can be both exciting and challenging. It's important to take a thoughtful, intentional approach to managing these funds, so that your decisions align with your broader financial goals and personal circumstances. Whether your priority is debt reduction, investing for the future, or funding family milestones, this is a chance to strengthen your financial foundation and make meaningful progress toward your objectives. Consider creating a plan before the cash arrives so you can act with confidence when the transaction completes.
Here are a few ideas to consider:
- Pay down high-interest debt like credit cards or personal loans.
- Invest the funds for long-term goals, such as retirement.
- Build a robust emergency fund that covers 3-6 months of living expenses.
- Fund a 529 plan for a child's or grandchild's education.
- Make a down payment on a new home or a vacation property.
While it's important to be responsible, don't forget to use a small portion of the proceeds to celebrate your success. Whether it's a family vacation or a special purchase, acknowledging your achievement is part of a healthy financial life.
Prepare Now, Benefit Later
The Abbott buyout of Exact Sciences represents a significant financial milestone for stockholders and employees. By preparing now and understanding exactly how this acquisition will impact your vested and unvested shares, you can develop a plan to maximize your benefits and minimize potential downsides. Keep in mind that federal withholding on supplemental income like vesting RSUs is typically set at a flat 22%—a rate that may not fully cover your true tax obligation. Thoughtful, proactive planning is essential to avoid surprises, particularly with a transaction of this size and complexity.
Partnering with a financial advisor who understands the specifics of the Exact Sciences acquisition can make a meaningful difference during this transition. An experienced advisor can help you estimate your after-tax proceeds from the Abbott deal, evaluate tax-saving opportunities tailored to your situation, and craft a step-by-step plan for how to put your cash payout to work for your long-term priorities. As additional details about the transaction become available in the coming months, your advisor can also help you adapt your strategy and ensure you’re making informed choices every step of the way. Starting these conversations now will give you greater clarity, confidence, and control as you navigate one of the most significant financial events of your career.